Designed novel nuclear localizing anticancer peptide targets p53 negative regulator MDM2 protein

Area of Science:

• Molecular Biology
• Oncology
• Drug Discovery

Background:

• Intracellular protein-protein interactions are key therapeutic targets for peptide-based anticancer agents.
• MDM2 oncogene product negatively regulates tumor suppressor p53 by promoting its degradation.
• Inhibiting MDM2-p53 interaction can restore p53 function, leading to cancer cell apoptosis.

Purpose of the Study:

• To design and evaluate a novel peptide, mPNC-NLS, targeting MDM2 for cancer therapy.
• To investigate the peptide's ability to restore p53 activity and induce apoptosis in cancer cells.
• To assess the peptide's efficacy and safety in preclinical cancer models.

Main Methods:

• Design of a novel peptide (mPNC-NLS) targeting the nucleus and MDM2 protein.
• In vitro assessment of apoptosis induction in A549 (lung) and U87 (glioblastoma) cancer cell lines.
• Cytotoxicity evaluation in normal lung fibroblast cells (WI38).
• Immunocytochemistry and Western blot analysis to confirm p53 and p21 activation.
• Assessment of peptide effect on 3D multicellular spheroid growth of A549 cells.

Main Results:

• The mPNC-NLS peptide effectively induced apoptosis in A549 and U87 cancer cells.
• The peptide demonstrated no significant cytotoxicity towards normal WI38 lung fibroblast cells.
• Western blot and immunocytochemistry confirmed mPNC-NLS activates p53 and p21 signaling pathways.
• mPNC-NLS significantly inhibited the in vitro growth of A549 3D multicellular spheroids.

Conclusions:

• The novel mPNC-NLS peptide is a promising anticancer agent that restores p53 tumor suppressor activity.
• mPNC-NLS effectively induces apoptosis in cancer cells via p53/p21 activation and inhibits tumor growth.
• The peptide's selective toxicity profile suggests potential for targeted cancer therapy with reduced side effects.